EnVVeno Medical Corporation Announces Proposed Public Offering

IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO), a company focused on treating venous disease, has announced a proposed public offering of its common stock. This offering, subject to market conditions, may also include pre-funded warrants. enVVeno plans to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares or warrants. The terms and size of the offering remain uncertain.

The company intends to use the proceeds primarily for the development of its two lead products, VenoValve and enVVe, as well as for general corporate purposes. Titan Partners Group will act as the sole bookrunner for this offering.

This offering will be made under a previously filed and effective shelf registration statement with the SEC. A preliminary prospectus supplement and base prospectus will be filed with the SEC and made available on its website.

This announcement does not constitute an offer to sell or buy the securities, nor will there be any sale of these securities in jurisdictions where such actions are unlawful without proper registration or qualification.